Results 271 to 280 of about 519,424 (350)

Personalized Medicine in Acute Myeloid Leukemia: Efficacy of a Novel Combination of Epigenetic Modifiers and a Tyrosine Kinase Inhibitor in Acute Myeloid Leukemia

, 2013
Ronald F. Siebenaler
openalex   +1 more source

Tyrosine Kinase Inhibitor XL228 [PDF]

, 2020
openaire   +1 more source

Dynamic Decoration of DNA Scaffolds for High‐Resolution Cancer Cell Subtyping

Advanced Science, EarlyView.
This study presents a dual‐mode imaging platform that utilizes self‐assembly and disassembly of DNA scaffolds for high‐resolution cancer cell detection. The structural rigidity of DNA scaffolds effectively prevents cellular internalization for over 300 min.
Xiaolin Hu, Jie Xie, Xinlin Guo, Liangting Wang, Zhengheng Yu, Xiaopei Qiu, Heng Li, Kang Wang, Xiaoxing Wang, Mingxuan Song, Junsong Guo, Wei Gu, Sergio Bernardini, Chaoyong Yang, Hong Zhang, Yang Luo   +15 more
wiley   +1 more source

Gene expression analysis of patients with chronic myeloid leukemia who discontinued tyrosine kinase inhibitor. [PDF]

Ann Hematol
Park H, Kim HJ, Sohn SK, Baik Y, Kim D, Lee SY, Kong JH, Kim H, Shin DY, Ahn JS, Park J, Park S, Kim I.   +12 more
europepmc   +1 more source

SIRT5–RAC2 Axis Drives Monocyte‐to‐Macrophage Differentiation to Promote Inflammatory Injury in Premature Ovarian Insufficiency

Advanced Science, EarlyView.
SIRT5 desuccinylates and stabilizes RAC2, activating CSF1R‐dependent signaling to drive monocyte differentiation into M0 macrophages and their polarization toward pro‐inflammatory M1 phenotypes in CTX‐induced premature ovarian insufficiency. Inhibiting the SIRT5‐RAC2 axis attenuates inflammation, reduces granulosa cell apoptosis, and preserves ...
Wenjing TanTai, Yaqi Li, Shengnan Liu, Minjuan Wu, Zhixiao Liu, Junfeng Jiang, Jingjing Chen, Xiaoding Xu, Li Li, Chaoqun Li, Fang Zhao, Ye Liu, Haitao Ni, Tengfei Zhang, Mingjuan Xu, Chaofeng Han   +15 more
wiley   +1 more source

Mechanisms and signaling pathways of tyrosine kinase inhibitor resistance in chronic myeloid leukemia: A comprehensive review. [PDF]

Leuk Res Rep
Lahmouad M, Rachid Z, Bellemrrabet R, Zerrouk J, Goh KW, Bouyahya A, Aboussalah Y.   +6 more
europepmc   +1 more source

Universal Antibody‐Engineered Lipid Nanoparticles Potentiate Chemo‐Immunotherapy Against Triple‐Negative Breast Cancer by Reprogramming Tumor Cell Metabolism

Advanced Science, EarlyView.
A universal ROR1 antibody‐engineered lipid nanoparticle (LNP) is constructed by sequential drug encapsulation and antibody conjugation. The LNP not only enables enhanced chemotherapeutic efficiency by targeting drug delivery and precise localization of deep‐seated tumors through NIR‐II fluorescence imaging, but also remodels immunosuppressive TME ...
Yeneng Dai, Jiaqi Wang, Yu Liu, Guanda Jiao, Yuheng Gu, Yang Liu, Shengyu Fu, Xing Fan, Jialin Li, Ziang Guo, Kam Tong Leung, Lipeng Zhu, Qi Zhao   +12 more
wiley   +1 more source

Fostamatinib (R788), a spleen tyrosine kinase inhibitor, sensitizes pancreatic cancer cells to oncolytic vesicular stomatitis virus. [PDF]

Mol Ther Oncol
Catacalos-Goad C, Goad DW, Holbrook MC, Krueger Q, Wilson IM, Hajjar MA, Grdzelishvili VZ.   +6 more
europepmc   +1 more source

BindingDB Entry 50022503: A novel small molecule met inhibitor induces apoptosis in cells transformed by the oncogenic TPR-MET tyrosine kinase.

Martin Sattler
openalex   +1 more source

2. Tyrosine Kinase Inhibitors

Nihon Naika Gakkai Zasshi, 2007
openaire   +2 more sources